Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Jiangsu Hengrui Pharmaceuticals Co's 10-Year RORE % for the quarter that ended in Mar. 2026 was 9.65%.
JHPCY's 10-Year RORE % is ranked better than 65.37% of 670
companies
in the Drug Manufacturers industry
Industry Median: 6.405
vs JHPCY: 9.65
Jiangsu Hengrui Pharmaceuticals Co (OTCPK:JHPCY) 10-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Jiangsu Hengrui Pharmaceuticals Co 10-Year RORE % Related Terms
Jiangsu Hengrui Pharmaceuticals Co 10-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co 10-Year RORE % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co 10-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
Jiangsu Hengrui Pharmaceuticals Co (JHPCY) has a 10-Year RORE % of 9.65 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #232 out of 670 companies in the Drug Manufacturers industry, placing it in the top 34.6%.
Is Jiangsu Hengrui Pharmaceuticals Co's 10-Year RORE % too high?
Jiangsu Hengrui Pharmaceuticals Co's current 10-Year RORE % is 9.65. The Drug Manufacturers industry median 10-Year RORE % is 6.41. Jiangsu Hengrui Pharmaceuticals Co's value of 9.65 is 50.7% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #232 out of 670 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's 10-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #232 out of 670 companies for 10-Year RORE %. This puts Jiangsu Hengrui Pharmaceuticals Co in the upper half of its industry. The industry median 10-Year RORE % is 6.41. Jiangsu Hengrui Pharmaceuticals Co's value of 9.65 is 50.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Drug Manufacturers company?
The median 10-Year RORE % among Drug Manufacturers companies is 6.41, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current 10-Year RORE % of 9.65 is 50.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median 10-Year RORE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current 10-Year RORE % is 9.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (JHPCY) is currently considered Modestly Undervalued. The stock's GF Value™ is $15.12, compared to a current price of $13.60 — trading 10.1% below its estimated fair value. The current 10-Year RORE % is 9.65 and 50.7% above the Drug Manufacturers industry median of 6.41. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (JHPCY), the current 10-Year RORE % is 9.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (JHPCY) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of $13.60 is trading 10.1% below its estimated GF Value™ of $15.12.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for JHPCY:
10-Year RORE %: 9.65
GF Value™: $15.12 vs. price of $13.60 (10.1% below fair value)
Industry Position: 50.7% above the Drug Manufacturers median (#232 of 670)
No single metric tells the full story. See the JHPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
71GF Score
Get the complete analysis for JHPCY
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JHPCY has been successfully added to your 
